Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
131.74
+1.02 (+0.78%)
Streaming Delayed Price
Updated: 1:58 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
February 26, 2024
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
February 26, 2024
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
Via
InvestorPlace
Behind the Scenes of Merck & Co's Latest Options Trends
February 26, 2024
Via
Benzinga
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
February 22, 2024
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Via
InvestorPlace
What the Options Market Tells Us About Merck & Co
February 15, 2024
Via
Benzinga
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
February 14, 2024
Via
Benzinga
Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock
February 02, 2024
Via
Benzinga
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
2 Monster Stocks to Buy Without Any Hesitation
February 22, 2024
Investors can sleep easy at night with these stocks in their portfolios.
Via
The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks
February 16, 2024
Via
Benzinga
Topics
Economy
Exposures
Economy
3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report
February 15, 2024
Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth.
Via
InvestorPlace
Drivers And Stock Pickers
February 13, 2024
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient.
Via
Talk Markets
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
February 12, 2024
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
February 09, 2024
Via
Benzinga
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
February 08, 2024
Investors are still excited about obesity treatments and weight-management drugs.
Via
The Motley Fool
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
February 05, 2024
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024."
Via
Benzinga
Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.
February 05, 2024
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued.
Via
Chartmill
7 Mutual Funds That Will Outperform in Any Market
February 03, 2024
While we’d all love to think we’re market geniuses, we could use the active management of outperforming mutual funds.
Via
InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
February 02, 2024
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn.
Via
InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Merck Stock Rocketed Nearly 5% Skyward Today
February 01, 2024
The company reported healthy sales growth and proffered encouraging guidance to boot.
Via
The Motley Fool
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.